Clinical trials: IgAN - IgA Nephropathy
IgA Nephropathy
Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
Treatment of prednisone plus cyclophosphamide may be superior to treatment of prednisone alone in patients with advanced-stage IgA nephropathy.
- Trial name
- TOPplus-IgAN (NCT01758120)
- Testing
- prednisone plus cyclophosphamide, Prednisone alone
- Where
- China
- Volunteers
- 135 people
- Sponsor
- Guangdong Provincial People's Hospital
IgA Nephropathy
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
The primary objective of this study is to evaluate the effect of OMS721 on 24-hour urine protein excretion (UPE) in IgA nephropathy (IgAN) patients with high baseline proteinuria (high-risk proteinuria group; 24-hour UPE ≥ 2…
- Trial name
- NCT03608033
- Testing
- OMS721, Vehicle (D5W or saline)
- Where
- 139 sites in United States, Argentina and 21 more
- Volunteers
- 360 people
- Sponsor
- Omeros Corporation
Primary IgA Nephropathy
Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef-301 and continue to be treated with a…
- Trial name
- Nefigard-OLE (NCT04541043)
- Testing
- Nefecon 16mg daily
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 119 people
- Sponsor
- Calliditas Therapeutics AB
IgA Nephropathy (IgAN)
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
Efficacy and safety of MY008211A in IgAN patients
- Trial name
- NCT06687174
- Testing
- MY008211A tablets
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Primary IgA Nephropathy
A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy
The purpose of this study is to evaluate the effectiveness and safety of IONIS-FB-LRx, an antisense inhibitor of complement factor B messenger ribonucleic acid (CFB mRNA), and to evaluate the effect of IONIS-FB-LRx on plasma…
- Trial name
- NCT04014335
- Testing
- IONIS-FB-LRx
- Where
- 7 sites in Australia, Canada and 2 more
- Volunteers
- 23 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
IgA Nephropathy (IgAN), Early Initial Therapy
A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
To observe of the efficacy and safety of early initiation of budesonide enteric coated capsules in the treatment of primary IgA nephropathy.
- Trial name
- NCT06676007
- Testing
- Gd-IgA1 test
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sichuan Provincial People's Hospital
IgA Nephropathy
Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis
The purpose of this study is to: 1. To evaluate the latest effects of TW for IgA nephropathy (IgAN) with asymptomatic abnormal urinalysis. 2. To evaluate the safety and tolerability of TW.
- Trial name
- NCT00885547
- Testing
- tripterygium wilfordii (TW)
- Volunteers
- 90 people
- Sponsor
- Nanjing University School of Medicine
IgA Nephropathy, Immunoglobulin A Nephropathy
Atrasentan in Patients With IgA Nephropathy
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
- Trial name
- ALIGN (NCT04573478)
- Testing
- Atrasentan, Zigakibart
- Where
- 135 sites in United States, Argentina and 18 more
- Volunteers
- 404 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
This is a Phase II, open-label study designed to To evaluate the safety and efficacy of NM8074 in reducing proteinuria relative to baseline in IgAN patients after 99 days of treatment.
- Trial name
- NCT06454110
- Testing
- NM8074
- Volunteers
- 10 people
- Sponsor
- NovelMed Therapeutics
Kidney Disease, Glomerulonephritis
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
This study will have two parts. The main aims are to: check the side effects from mezagitamab. check for long-term side effects from mezagitamab.
- Trial name
- NCT05174221
- Testing
- Mezagitamab
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 17 people
- Sponsor
- Takeda
Immunoglobulin A Nephropathy
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.
- Trial name
- NCT06564142
- Testing
- Povetacicept
- Where
- 318 sites in United States, Australia and 31 more
- Volunteers
- 605 people
- Sponsor
- Alpine Immune Sciences Inc, A Subsidiary of Vertex
Healthy Subjects
Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension
This single-center, open-label, randomized, single and multiple-dose, 3-way sequential study at 3 dose levels will be performed in healthy subjects. Subjects will be randomized to 1 of the 3 dose levels.
- Trial name
- NCT05562362
- Testing
- RE-021, sparsentan
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Travere Therapeutics, Inc.
Recurrent IgA Nephropathy
Rituximab in Recurrent IgA Nephropathy
Currently, the treatment options of recurrent IgA nephropathy (IgAN) are conflicting and largely based on expert opinions. Consequently, the recent KDIGO clinical practice guideline for the care of kidney transplant recipients…
- Trial name
- NCT02571842
- Testing
- Intravenous Rituximab, ACEI/ARB and corticosteroids
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Chulalongkorn University
Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months.
- Trial name
- NCT06797518
- Testing
- Iptacopan
- Where
- 19 sites in United States, Argentina and 3 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy, Proteinuria
Acthar on Proteinuria in IgA Nephropathy Patients
IgA nephropathy occurs when IgA-a protein that helps the body fight infections-settles in the kidneys. IgA deposits may cause the kidneys to leak blood and sometimes protein in the urine.
- Trial name
- NCT02382523
- Testing
- Acthar 80 unit injection
- Where
- United States
- Sponsor
- Baylor College of Medicine
IgA Nephropathy, Focal Segmental Glomerulosclerosis
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.
- Trial name
- NCT05942625
- Testing
- HS-10390 tablet
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Hansoh BioMedical R&D Company
Immunoglobulin A Nephropathy
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
- Trial name
- PROTECT (NCT03762850)
- Testing
- sparsentan, irbesartan, Dapagliflozin
- Where
- 162 sites in United States, Australia and 16 more
- Volunteers
- 406 people
- Sponsor
- Travere Therapeutics, Inc.
IgA Nephropathy (IgAN)
Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients
This study at UCLA Center for Health Sciences is testing whether the Autoimmune Protocol (AIP) diet can lower protein levels in the urine of people with IgA Nephropathy (IgAN), a common kidney disease that can lead to kidney…
- Trial name
- NCT07022574
- Testing
- Low inflammation diet intervention
- Where
- United States
- Sponsor
- University of California, Los Angeles
Obstructive Sleep Apnea, IgA Nephropathy
The Effect of OSA on Severity and Prognosis of Patients With IgAN
This study aims to investigate the influence of obstructive sleep apnea hypopnea syndrome (OSA) on the severity and prognosis of patients with IgA nephropathy (IgAN), and to evaluate the therapeutic effect of continuous positive…
- Trial name
- NCT06393036
- Testing
- Continuous Positive Airway Pressure
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital
IgA Nephropathy (IgAN)
A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
This is a Phase IIIb, multicenter, two-arm, randomized, double-blind, parallel group study to evaluate the efficacy and safety of zigakibart + atrasentan compared to zigakibart + placebo in patients with primary IgAN at risk of…
- Trial name
- LUMINA IgAN (NCT07850752)
- Testing
- zigakibart, atrasentan
- Volunteers
- 340 people
- Sponsor
- Novartis Pharmaceuticals